|
The other issue
that’s important to remember, and that’s relevant to future trials, is that maybe the
meta-analysis doesn’t work. There may be a meta-analysis that suggests benefit because
in a large multi-center trial you have a very non-homogenous population. A disease like
preeclampsia, as we’ve researched into that, may come about for lots of different
reasons, and when you mix lots of different people together you don’t see it anymore,
and only certain subsets will benefit. Now that’s only of the explanations. The
explanations on the previous slide are every bit as valid but it’s something to keep
stuck in your mind in this setting, and probably in other settings of poorly designed
diseases too. |